Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023GlobeNewsWire • 10/11/23
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)GlobeNewsWire • 08/24/23
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)Business Wire • 08/24/23
Compared to Estimates, Royalty Pharma (RPRX) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/08/23
Royalty Pharma (RPRX) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/08/23
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023GlobeNewsWire • 07/18/23
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceGlobeNewsWire • 06/07/23
Royalty Pharma (RPRX) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/09/23